Core Insights - Syra Health Corp. has appointed Gregory R. Alexander as the new Chief Executive Officer, effective January 5, 2026, to drive growth and market expansion [1][3] Company Overview - Syra Health is a healthcare solutions company focused on improving health outcomes through prevention-focused, accessible, and affordable solutions [1][7] - The company specializes in healthcare prevention, expanding access, and delivering affordable solutions, with capabilities in healthcare analytics and digital health solutions [7] Leadership Background - Gregory R. Alexander has over two decades of P&L experience and a proven track record in driving growth, operational excellence, and strategic change in managed care, population health, and healthcare technology [2][3] - His previous roles include Senior Vice President of Commercial at Ellipsis Health and Chief Growth Officer at CitizensRx, where he implemented growth strategies that tripled sales [4] Strategic Goals - Alexander's leadership is expected to accelerate Syra Health's growth strategy, leveraging his expertise in Medicare, Medicaid, and population health services [3][5] - The company aims to expand its market presence and deliver greater value to customers, shareholders, and communities [5] Community Engagement - Alexander is a long-time resident of Carmel, Indiana, and has led significant healthcare initiatives in the state, including supporting Indiana University Health System's $600 million health plan [5]

Financial Data and Key Metrics Changes - The company reported weaker financial results for Q3 2025, with a 5% decline in total adjusted EBITDA primarily due to performance in Mexico [6][9] - Adjusted net income was PEN 58 million for the quarter, with FX-neutral consolidated revenue increasing by 1% [9][22] - Capacity utilization decreased by 3 percentage points to 64%, with a 1.5 percentage point increase in Peru offset by declines in Colombia and Mexico [9][10] Business Line Data and Key Metrics Changes - Peru's revenue grew by 9% and adjusted EBITDA increased by 15%, driven by improved healthcare pricing mix and strong insurance MLR [9][19] - Colombia's revenue grew by 5%, with adjusted EBITDA increasing by 18%, attributed to risk-sharing models and higher average tickets for surgery [20][21] - Mexico experienced a 12% revenue decline, although surgery volumes and oncology services increased [11][12] Market Data and Key Metrics Changes - Peru accounted for over half of the company's revenues, continuing to be a strong growth driver [21] - Colombia's share of revenues from major government payers decreased from 20% to 13%, indicating successful diversification efforts [20][21] - Mexico's revenue decline was influenced by a slower market and operational challenges, including the implementation of new IT systems [12][21] Company Strategy and Development Direction - The company is focused on capturing long-term growth opportunities in Mexico, anticipating a full recovery in 2026 [8][30] - Auna is rolling out new service offerings and enhancing collaboration with physicians to penetrate profitable market segments [14][15] - The partnership with Sojitz Corporation aims to accelerate growth in Mexico while maintaining a disciplined deleveraging path [31][35] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about Mexico's recovery, highlighting stable hospital operations and increased service volumes [6][8] - The company remains committed to improving its leverage ratio to below three times net debt to EBITDA in the medium term [26][27] - Management acknowledged the challenges in Colombia but emphasized the strength of Auna's positioning and growth potential [36][38] Other Important Information - Auna successfully refinanced $765 million in debt, improving its debt profile and extending maturities [26][27] - The company is implementing a comprehensive IT system to enhance operational efficiency and data management [18] Q&A Session Summary Question: Future strategy in Mexico and the rationale for expanding - Management clarified that the partnership with Sojitz is aimed at accelerating growth in Mexico while maintaining leverage targets [34][35] Question: Potential changes in Colombia's leadership and their impact - Management indicated that while political changes may not yield immediate improvements, there are signs of stabilization in the Colombian healthcare sector [36][38] Question: Key KPIs to track for recovery in 2026 - Management highlighted occupancy, payer mix, and surgical productivity as critical KPIs to monitor for tangible recovery [44] Question: Recent share price weakness and institutional investor activity - Management noted that the current share price does not reflect the company's fundamentals and is evaluating options to enhance shareholder value [45] Question: Return on investment timeline for Mexico performance - Management expects 2026 to be a growth year for Mexico, despite setbacks in 2025 [47] Question: Expansion plans in Peru and Mexico - Management confirmed plans to increase capacity in both countries, focusing on high-complexity services [48] Question: Details on the partnership with Sojitz and investment plans - Management confirmed that the $500 million investment plan is related to the MoU with Sojitz, aimed at significant top-line growth [49][50]